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Abstract
Background: Stimulating successful tobacco cessation among employees has multiple benefits. Employees who
quit tobacco are healthier, more productive, less absent from work, and longer employable than employees who
continue to use tobacco. Despite the evidence for these benefits of tobacco cessation, a successful method to
stimulate employees to quit tobacco is lacking. The aim of this study is to evaluate whether adding a financial
incentive to behavioral support (compared with no additional incentive) is effective and cost-effective in increasing
abstinence rates in tobacco smoking employees participating in a smoking cessation group training.
Methods/design: In this cluster-randomized trial employees in the intervention and control group both participate in a
smoking cessation group training consisting of seven weekly counseling sessions of ninety minutes each. In addition to
the training, employees in the intervention group receive a voucher as an incentive for being abstinent from smoking
at the end of the training (€50), after three months (€50), after six months (€50), and after one year (€200). The control
group does not receive any incentive. The primary outcome is carbon monoxide validated 12-month continuous
abstinence from smoking (Russel’s standard). Additionally, an economic evaluation is performed from a societal and an
employer perspective.
Discussion: The present paper describes the methods and design of this cluster-randomized trial in detail. We
hypothesize that the financial incentive for abstinence in the form of vouchers increases abstinence rates over and above
the group training. The results of this study can provide important recommendations for enhancement of employee
tobacco cessation.
Trial registration: Dutch Trial Register: NTR5657. First received 27-01-2016.
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Background
Tobacco use is a major health threat and responsible for
deaths due to cancer, chronic obstructive pulmonary
disease (COPD), coronary heart disease, stroke and heart
failure [1]. The life expectancy for smokers is at least
10 years shorter than for nonsmokers [1, 2]. Not only is
smoking a serious health risk, it is also responsible for
an estimated 8.7 % of annual healthcare costs in the US
[3]. Employees who smoke also represent a significant
cost to their employers [4]. These costs can be distin-
guished as the cost due to sickness absenteeism and the
cost due to smoking breaks. Smokers are about 1.5 more
days per year absent from work than non-smokers [5, 6].
Smoking is associated with absenteeism [5, 7], and with
reduced performance [8, 9]. The amount of time that
employees spend smoking each workday depends on
several factors, such as the number of smoking breaks
and whether the employee has to go outside to smoke.
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An employee who works fulltime and takes four smok-
ing breaks of ten minutes per day spends about 150
(work) hours per year on smoking. It was estimated that
in the US, employees who smoke cost their employer an
excess of $5816 per smoker per year [4]. On the other
hand, when employees quit smoking, their absenteeism
declines within several years [5]. In addition, the prod-
uctivity of former smokers is higher than that of current
smokers [5]. It is therefore profitable for employers to
invest in smoking cessation both from a company per-
spective as well as from a societal viewpoint.
An approach in stimulating employees to stop smoking
is to use incentives for quit success. The rationale behind
incentives for healthy behavior is twofold. Firstly, people
value present benefits and costs more than future ones
[10]. Secondly, people are more motivated by tangible
gains such as a financial benefit, than by long-term intan-
gible gains like a reduction in the chance of negative health
outcomes. These two irrational ‘decision biases’ can be
used to nudge people toward healthy behavior that is bene-
ficial for them in the long run [11]. An incentive in the
form of money or vouchers can be the immediate, concrete
reward which can motivate people to stop smoking.
Several studies have shown that financial incentives for
smoking cessation success can be an effective method to
stimulate smoking cessation [12–18]. For instance, incen-
tives have proven to be successful in increasing continu-
ous abstinence in pregnant women [15], in homeless
smokers [16], and in substance abusers [17]. A long-term
study by Volpp et al. [18] conducted in the United States
involved 878 participating employees of a multinational
corporation. Participants were given the opportunity to
follow behavioral counseling for smoking cessation near
their hometown and, if desired, in combination with
pharmacological treatment. Both behavioral counseling
and medication were fully reimbursed by the employer.
Participants in the intervention group received an incen-
tive of $100 for completing a smoking cessation program,
$250 for smoking abstinence at 6 months after study
enrollment, and $400 for smoking abstinence at 12 months
after study enrollment. Participants in the intervention
group (with incentive) were significantly more likely to be
completely abstinent after 6, 12, and 15 months than in
the control group. Furthermore, participants in the inter-
vention group were more likely to have started a smoking
cessation program and to have completed the program.
While incentives thus can motivate smokers to enroll in a
cessation program, only few participants in the Volpp
study [18] actually did enroll (incentive group 15.4 % vs
control group 5.4 %). Importantly, the rate of quitters was
substantially higher in participants from the incentive
group who participated in the smoking cessation program
than participants from the control group who enrolled in
the training (46.3 % vs 20.8 %). It is therefore likely that
the combination of an effective smoking cessation pro-
gram with incentives for quit success will prove to be the
most effective in increasing smoking cessation rates.
The chance to quit successfully increases when people
receive professional stop smoking support [19]. Yet, smok-
ing cessation treatment is relatively expensive for people
with low incomes and the cost of medication can be a bar-
rier [20]. Since a lower income is also related to a higher
smoking prevalence [21], it is particularly important to
make smoking cessation counseling accessible for people
with lower incomes. If smoking cessation therapy is fully
reimbursed, more smokers will make use of it which can
lead to twice as many long term quitters [22, 23]. It is
therefore conceivable that smokers are more willing to
start a smoking cessation treatment when their employer
accounts for the costs. For a smoking cessation training
combined with incentives to be widely adopted by com-
mercial companies as a common smoking cessation inter-
vention, it needs to be cost-effective. To our knowledge,
no study that has investigated the effect of incentives on
long-term smoking abstinence in a workplace setting has
incorporated an economic evaluation. We are only aware
of a randomized controlled trial in pregnant women which
found that incentives of 400 pounds were highly cost-
effective [24]. Smoking cessation training in combination
with incentives might therefore be attractive to employers
in light of employee health improvement but also from a
cost saving perspective.
The proposed study: “Continuous Abstinence Through
Corporate Healthcare” (CATCH) is conducted in Dutch
companies. Currently, about a quarter of Dutch adults
smoke. Smoking prevalence is much higher among low
(28 %) and moderate educated adults (27 %) than among
high educated adults (19 %) [25]. This socioeconomic dif-
ference has been increasing over time in the Netherlands
[26]. The higher prevalence of smoking in individuals
from lower socioeconomic groups is the single most im-
portant cause of socioeconomic differences in mortality
[27, 28]. In order to decrease these differences, it is vital to
specifically target the lower socioeconomic population.
The aim of this study is to investigate whether financial
incentives combined with a smoking cessation training
can improve quit success. In addition, an economic evalu-
ation is conducted to assess the costs and benefits of this
intervention. The results of this study can provide key evi-
dence for the applicability and effectiveness of incentives
for smoking cessation and can offer recommendations for
implementing incentives to reduce employee smoking in a
corporate context.
Methods/design
The primary aim of this study is to evaluate whether adding
a financial incentive (compared with no additional incen-
tive) is effective and cost-effective in increasing 12-month
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continuous abstinence rates in tobacco smoking employees
participating in a smoking cessation group training. A sec-
ondary aim is to investigate the effect of the incentive on
the quit rate immediately after the training, after three and
after six months. Furthermore, this study investigates the
cost-effectiveness of the incentive in terms of quit rate and
utilities, both from a societal perspective and from the em-
ployer’s perspective.
A cluster-randomized controlled trial is conducted in
44 Dutch companies who offer their employees an
evidence-based treatment for smoking cessation. Partici-
pants from the intervention companies receive incentives
when smoking abstinence is achieved at a fixed time
schedule (Fig. 1), whereas participants from the control
companies do not receive incentives (care as usual).
Study population
Approximately 516 tobacco smoking employees, ran-
domized from 22 intervention companies and 22 control
companies, participate in this study. To be eligible for
participating in the study, companies have to meet cer-
tain criteria: (1) the management is willing to pay for the
counseling sessions and (2) the management agrees that
employees participate in the counseling sessions and
Fig. 1 Flow-chart of design and measurements
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carbon monoxide (CO) measurements during working
hours or directly after on a location arranged by the com-
pany. In order to be eligible to participate in this study, an
employee needs to be a current tobacco smoker and at
least 18 years old. At the request of the employer, spouses
who smoke are allowed to enroll in the study. Subjects are
not eligible for participation in this study when they have
an acute life-threatening disease, are not able to read or
speak the Dutch language, or have already started an
attempt to quit smoking at the moment of inclusion.
Recruitment
In order to recruit companies, SineFuma - an organization
that provides smoking cessation group training to compan-
ies - presents their clients with the possibility of participat-
ing in this research project. Additionally, the research
assistant actively approaches companies by telephone and
via a recruitment letter sent by post or e-mail with a visu-
ally attractive flyer attached. Press releases, media inter-
views and social media (Facebook, LinkedIn, Twitter) are
used to create awareness of the study, and advertisements
are placed in digital newsletters of several organizations,
such as the Dutch Cancer Society and Lung Alliance
Netherlands. Companies are targeted based on number of
employees (n > 200) and socioeconomic status of employees
(preferably lower educated workers).
In the recruitment process, companies are informed
that they can be randomized to the incentive group or
the control group. To which group the company is
assigned is revealed during the first session of the smok-
ing cessation training. This means that a company needs
to decide to participate in the research without knowing
the final result of the randomization.
When a company decides to participate in the study,
participants within the company are recruited using ad-
vertisements via the corporate website, email, posters and
informative flyers that are spread through the company
building. On these promotion materials it is advertised
that participants have a chance to earn financial incentives
with a total amount of 350 euro. On request of the com-
pany, SineFuma or the research assistant organizes an
informal presentation at the company to inform em-
ployees who consider participating in the training. Prior to
enrolling in the study, employees receive an information
letter and are asked to give their signed informed consent.
In this information letter, the chance of being eligible to
earn the financial incentives is explained, and detailed in-
formation on the smoking cessation training and the re-
search procedures is provided.
Intervention
Smoking cessation counseling
Evidence-based smoking cessation counseling is provided
by experienced trainers of SineFuma to both employees in
the intervention companies and the control companies.
Groups of approximately 8–16 participants receive coun-
seling in seven sessions of ninety minutes on a location ar-
ranged by the company. The training is practical in nature
and focuses on ways to quit successfully and how to avoid
relapse. It relies on a buddy system group dynamic to ef-
fectively promote peer support. The trainer informs par-
ticipants about the possibility to use smoking cessation
aids like nicotine replacement therapy and medication
during their quit attempt. The company decides whether
it reimburses the medication or if their employees have to
claim it from their health insurance. After two sessions in
which the participants are prepared, they stop smoking at
the third session. In session four to seven, the participants
receive counseling to get through the first difficult weeks
of smoking abstinence. As a standard part of the smoking
cessation training, participants perform a CO measure-
ment every week starting the second session, which serves
as a tool to motivate and encourage them to stay quit.
Incentives
As part of the intervention, participants from the inter-
vention group who are continuously abstinent from smok-
ing receive financial incentives. There is a fixed time
schedule for the incentives to help maximize the effect on
smoking cessation success. At T1, T2, and T3, participants
who report to have been abstinent since the end of the
smoking cessation training (continuous abstinence) and
who have a CO score lower than 10 ppm [29] at the re-
spective visit receive €50 credit. At T4, abstinent partici-
pants are given credit representing a value of €200.
Participants who did not succeed in quitting smoking at
T1 get a second chance to earn a voucher at T2 and to be
eligible for the vouchers at T3 and T4 if they are verifiable
smoking abstinent at T2 (point prevalence abstinence).
The participants receive a digital code by e-mail which
they can use to access a digital gift shop where they can
exchange their voucher for a broad range of products and
activities.
Outcomes
The primary outcome is carbon monoxide validated
12 months (T1-T4) continuous abstinence from smoking
(Russel’s standard) [29]. This is evaluated by self-report
of smoking and validated by biochemical measurements.
Self-report of smoking abstinence is assessed by measur-
ing seven-day point prevalence abstinence and pro-
longed abstinence [29] and biochemically verified using
a CO measurement. Abstinence is defined as smoking
not more than five cigarettes from the start of the
abstinence period. Secondary outcomes are smoking ab-
stinence immediately after smoking cessation counseling
(T1), after three months (T2) and after six months (T3).
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The same methods and definitions to determine smok-
ing abstinence are used as for the primary outcome.
Carbon monoxide measurement
Smoking abstinence is biochemically validated by measur-
ing expired air carbon monoxide concentrations using a
cut-off point of 9 parts per million among those who report
having quit smoking using a handheld monitor (PiCO™
Smokerlyzer, Bedfont Scientific Ltd., Kent, England). This is
a non-invasive and reliable method to detect recent smok-
ing [29]. As a part of the smoking cessation training, partic-
ipants will perform a CO measurement in session 2–7.
After the training, CO measurements will be performed by
the research assistant to validate smoking abstinence. The
validation takes place at the company within two weeks
after distribution of the questionnaire at T1, T2, T3, and
T4. When there is discordance between self-report of
smoking abstinence and biochemical validation or when
participants do not cooperate with biochemical validation,
participants are assumed to be smokers [29].
Questionnaires
Participants fill out web-based questionnaires about their
smoking and cessation behavior, use of resources (health
care and other societal costs), and generic quality of life at
T0 - T4. At T0, participants are asked about demographic
characteristics, current and past smoking (cessation) behav-
ior, number of pack years smoked [30], quit intention, use
of smoking cessation treatment, and nicotine dependence
[31]. At T1, participants are asked to evaluate the counsel-
ing sessions via multiple choice questions concerning the
quality of the training and the coach, the individual compo-
nents of the training, and the fact that the training was
organized within the company. At T1 - T4, self-report of
smoking abstinence is assessed by measuring seven-day
point prevalence abstinence and prolonged abstinence [29].
At T4, participants from the intervention group are asked
to evaluate the incentives via five multiple choice questions
about appreciation of the incentives and their perceived
effectiveness. At all measurement points, participants are
asked about quit intention, use of smoking cessation treat-
ment, nicotine dependence, stress, attitudes, self-efficacy,
risk perception, (peer) social support, smoking regulations
at the workplace, medical care and medication use.
Process evaluation
A process evaluation, consisting of questionnaires and
interviews, is conducted to assess participants’ experi-
ence with the study. At 6 months after the smoking ces-
sation training, qualitative interviews are conducted with
participants from the intervention companies who quit
smoking successfully and participants from the interven-
tion companies who did not. At least 15 interviews are
conducted, after which the point of data saturation will
be reached if in three further consecutive interviews no
new themes or relationships between themes have
emerged [32]. From the participants who did not man-
age to quit, participants are interviewed who did not ac-
complish smoking abstinence in the early phase during
the training, and participants who relapsed later on. The
aim of the interviews is to gain insight in the partici-
pants’ motivation to enroll in the training, to hear their
opinion on the effect of the incentive and to inquire
their appraisal of the program. The interviews are re-
corded, transcribed and coded using NVivo software.
Coding is performed by two independent researchers.
Discrepancies are discussed with a third researcher.
Researchers involved in interviewing and data analysis
keep a diary to evaluate their own subjective views on
the interpretation of the data.
Sample size calculation
The study from Volpp et al. [18] is used to obtain esti-
mates for the sample size calculation. After 12 months,
15 % of participants in the intervention group and 5 %
in the control group were abstinent. With an alpha of
0.05, the required sample size to obtain this clinically
relevant effect size with 80 % power is 141 participants
per treatment group, based on the Chi-square test.
Since the randomization is on cluster (company) level
and assuming a mean number of participants per com-
pany (m) of 12 and an intra-class correlation (ICC) of
0.05 [31], the design effect 1 + (m-1) ICC = 1.55, yields a
sample size of 219 participants per group. Taking into
account 15 % loss to follow up due to unexpected em-
ployee turnover [18], 516 participants (44 companies)
have to be included in the study in total.
Randomization
Participants are allocated via cluster-randomization on a
company level to the intervention or control group. For
large corporations with several branches in which the par-
ticipants are not in direct contact with each other, each
location is entered separately in the randomization. The
randomization procedure is performed by an independent
research assistant. The sequence of the randomization is
generated with a digital randomization program using the
biased urn method [33, 34], where the proportion of being
randomized into a group is inversely related with the
proportion of participants who are already randomised
into that group, in order to maintain treatment balance
throughout the trial.
Statistical analysis
Based on the intention-to-treat principle, all randomized
participants are included in the denominator for calcu-
lating abstinence rates with the exception of unavoidable
loss to follow-up as stated the Russel Standard [29]. The
van den Brand et al. BMC Public Health  (2016) 16:1056 Page 5 of 9
primary effectiveness analysis examines the difference in
prolonged smoking abstinence between intervention
group and control group over a period of twelve months
after the counseling sessions. To be able to account for
repeated measures and nesting of participants within
companies, generalized mixed models with the logit link
are used. Time, group (intervention or control) and the
interaction between time and group are entered in the
model as fixed factors. Baseline measurements such as
socioeconomic status (based on income and education)
and nicotine dependence are considered as potential ef-
fect modifiers, and will therefore be explored by moder-
ation in the analysis. If those are indeed effect-modifiers,
the effects for each level of socioeconomic status and
nicotine dependence are reported. In case of missing
values in these potential effect modifiers, multiple im-
putation approach is used. Missing data in the outcome
variable are not being imputed, since the likelihood-
based approach is used to deal with missing values [35].
A two-tailed test is considered statistically significant
with p-values <0.05.
Economic evaluation
An economic evaluation in the form of a cost-effectiveness
(CEA) and cost-utility analysis (CUA) from a societal per-
spective and from an employer’s perspective [36] is embed-
ded in this trial-based economic evaluation. The time
horizon and the measurement point are combined with the
effectiveness study, i.e. the T0-T4 measurement. The pri-
mary outcome for the CEA is cost per continuously abstin-
ent ex-smoker. The primary outcome of the CUA is cost
per Quality Adjusted Life Year (QALYs). The utility value
derived from the standard quality of life questionnaire,
EuroQol 5D5L [37], using Dutch tariff [38] will be used to
compute QALYs. The utilities at the various time points are
used to compute QALYs by means of the area under the
curve method [39].
As this economic evaluation is also performed from a
societal perspective, this implies that all relevant costs
and outcomes are taken into account. A separate ana-
lysis is performed from the employer’s perspective. It is
hypothesized that the intervention is associated with an
increased number of quitters, increase in quality of life,
and decreased costs. The time horizon is 12 months.
Costs (the use of resources) are measured continuously;
outcomes for the economic evaluation study are mea-
sured before the start of the smoking cessation training,
at 3 months, 6 months, and 12 months.
Cost measurement
Total costs are estimated using a bottom-up (or micro-
costing) approach, where information on each element of
service used is multiplied by an appropriate unit cost and
summed to provide an overall total cost. Intervention
costs, healthcare costs, respondent and family costs, and
costs outside the health care sector are assessed, especially
the cost for the employer. A cost questionnaire was espe-
cially designed for this study, based on existing question-
naires [40–43], which identifies all relevant costs aspects.
Subjects are asked to report the data from their cost ques-
tionnaire relating to the previous 3 months at T0, and
relating to the period in between measurements at T1-T4.
The valuation of costs is based mainly on the updated
Dutch manual for cost analysis [44]. Cost prices are
expressed in 2017 euros. If necessary, existing cost-prices
are updated to 2017 using the consumer price index.
Analysis of economic evaluation
The analysis of the economic evaluation contains several
uncertainty analyses, including bootstrapping analysis
for sample uncertainty. The results of the economic
evaluation are presented in cost-effectiveness plane and
cost-effectiveness acceptability curves (CEAC). The
Incremental cost-effectiveness ratio (ICER) is deter-
mined on the basis of incremental costs and effects of
evidence-based interventions for smoking cessation in a
corporate setting compared to care as usual. The cost-
effectiveness ratio is stated in terms of costs per out-
come rate, the cost-utility ratio focuses on the net cost
per Quality Adjusted Life Year gained.
The ICER is calculated as follows. ICER = (Ci – Cc)/
(Ei – Ec), where Ci is the annual total cost of the
evidence-based interventions for smoking cessation in a
company setting group, Cc is the annual total cost of the
care as usual group, Ei is the effects at one year follow-
up for the evidence-based interventions for smoking ces-
sation in a company setting group and Ec is the effect at
one year follow-up for the care as usual group.
The robustness of the ICER is checked by non-parametric
bootstrapping. Bootstrap simulations are also conducted
in order to quantify the uncertainty around the ICER,
yielding information about the joint distribution of cost
and effect differences. The bootstrapped cost-effectiveness
ratios are subsequently plotted in a cost-effectiveness
plane, in which the vertical line reflects the difference in
costs and the horizontal line reflects the difference in ef-
fectiveness. The choice of treatment depends on the max-
imum amount of money that society is prepared to pay
for a gain in effectiveness, which is called the ceiling ratio.
Therefore, the bootstrapped ICERs are also depicted in a
cost-effectiveness acceptability curve showing the prob-
ability that evidence-based interventions for smoking ces-
sation in a business setting is cost-effective using a range
of ceiling ratios. Additionally, to demonstrate the robust-
ness of our base-case findings, a multi-way sensitivity ana-
lysis is performed. In the sensitivity analysis, uncertain
factors of assumptions in the base case analysis are recal-
culated in order to assess whether the assumptions have
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influenced the incremental cost-effectiveness ratio (ICER),
for example by varying cost-prices and volumes between
minimum and maximum [45].
Discussion
This paper presents the protocol of the intervention
study “Continuous Abstinence Through Corporate
Healthcare” (CATCH). The aim of the study is to inves-
tigate the effectiveness of incentives on continuous ab-
stinence in employees. A total of 516 employees, divided
over 22 control and 22 intervention companies partici-
pate in a cluster-randomized controlled trial. In both
groups, participants follow a seven-week smoking cessa-
tion program. In the intervention group, employees add-
itionally receive vouchers for cessation success up to a
total value of 350 euro. It is hypothesized that employees
in the incentive group achieve a higher 12-month con-
tinuous abstinence rate.
Strengths and limitations
The proposed study has several strengths, starting with
its company setting. A company setting can have several
advantages compared to other settings; corporations
have the potential to reach a large amount of people,
can motivate their employees to participate and thereby
achieve high attendance rates, and may inspire peer sup-
port and positive peer pressure among colleagues [46].
Moreover, businesses have an interest in keeping their
employees healthy [4].
Another strong point of this study is that the proposed
study performs a cost-effectiveness and cost-utility analysis
from a societal perspective and specifically from an
employer’s perspective. To our best knowledge, the cost-
effectiveness of financial incentives to stimulate long term
smoking cessation in a company setting has not been estab-
lished yet. The outcomes of the cost-effectiveness analysis
can help inform employers who are considering providing
smoking cessation support in combination with incentives
for their employees.
What makes this study also particularly relevant is its
target population of employees with a lower socioeco-
nomic status. People with a lower education and income
smoke more often [25, 47], smoke more cigarettes per day
and have lower quit rates than people with a higher SES
[26, 48]. Although smokers with low SES are as likely to
start a quit attempt as smokers with a high SES, they are
less likely to succeed in quitting smoking [49]. Potential
barriers in quitting successfully are suggested to be lack of
social support and financial barriers to smoking cessation
treatment [47]. The current intervention aims to remove
potential obstacles and to make the smoking cessation
program easily accessible for employees in three ways: (1)
by providing it via the employer, (2) by organizing the
training sessions at the workplace, and (3) by designing
the training as a group program so that colleagues can
support each other both during and between sessions.
A possible limitation of this study is the lack of blind-
ing of the research participants to the existence of the
intervention and control conditions. It is expected that
the incentive group is more attractive to subjects than
the control group. If smokers would know for certain
that the incentive is within reach, it could lead to em-
ployees signing up who only smoke occasionally and
are not dependent on the training for a successful quit
attempt. In contrast, the control group may appeal only
to heavy smokers who are highly motivated to quit. If
nothing would be arranged to avoid these potential
problems, it was anticipated that the study would end
up with a substantial larger number of subjects in the
intervention condition than in the control condition,
which could cause selection bias. To avoid this possibil-
ity, it was decided not to randomize participants prior
to enrolment, but to inform them merely about their
50 % chance of being eligible to earn the vouchers.
Only after enrolment, during the first training session,
it is revealed whether participants are randomized into
the control or intervention condition. This approach
could, however, lead to attrition bias, when participants
in the control group are disappointed about not being
able to earn the vouchers and therefore drop out more
frequently. Furthermore, it is anticipated that some
larger companies will participate with more than one
group. In order to avoid inequality among coworkers, it
was decided that all groups within the same location of
the corporation would be randomized together. A
disadvantage of this decision is that when these groups
do not start at the same time, it could cause selection
bias, since employees in the second group of the
company may find out whether they will receive the
incentive or not.
Conclusion
The proposed study is the first in the Netherlands that
investigates the effect of financial rewards on smoking
cessation and the first study worldwide that assesses the
cost-effectiveness of incentives to decrease smoking in
employees. The results of this study can provide import-
ant recommendations for the use of financial incentives
to motivate employees to quit smoking.
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